{"id":"W4410804815","doi":"10.1200/jco.2025.43.16_suppl.2515","title":"An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Monoclonal antibody; Solid tumor; Cancer research; Antibody; Oncology; Internal medicine; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008849882,0.001505925,0.001501568,0.0003989495,0.0003452032,0.0009663408,0.0007551238,0.000845063,0.004236968],"category_scores_gemma":[0.0006691872,0.0005165486,0.0007506247,0.0004121189,0.0008778872,0.0009046696,0.0003463493,0.002403977,0.001129091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001325386,"about_ca_system_score_gemma":0.001614795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001415582,"about_ca_topic_score_gemma":0.003875417,"domain_scores_codex":[0.9997167,0.0001075719,0.00001441986,0.00005321783,0.00003014666,0.00007795919],"domain_scores_gemma":[0.9995806,0.00005715951,0.00008950162,0.00002440758,0.00002464752,0.0002236688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8396058,0.05713541,0.003155605,0.000623939,0.0006995416,0.0001760427,0.0002099476,0.002511294,0.02541567,0.0002700497,0.002986395,0.06721041],"study_design_scores_gemma":[0.5069195,0.4796459,0.006377813,0.00003138973,0.0002975191,0.0002016741,0.0000691083,0.001593168,0.00223242,0.000177345,0.002431124,0.0000230048],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919508,0.001780314,0.0004164936,0.0003224462,0.0001282138,0.002191698,0.0008781187,0.00009532674,0.002236699],"genre_scores_gemma":[0.9914498,0.001143702,0.001019715,0.0004597836,0.00013329,0.001916786,0.001535562,0.00002047002,0.002320934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004236968,"threshold_uncertainty_score":0.01417404,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0392421339156431,"score_gpt":0.4236416349096234,"score_spread":0.3843995009939803,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}